Source: CureToday articles
The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.
Recent Content
- Asembia AXS25: Navigating Challenges in Cell and Gene Therapy
- Targeted Therapies Transform CLL Care: Inside the Era of BTK and BCL-2 Inhibitors
- Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act
- An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
- AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death
- Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
- Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
- TAR-200 Shows High Response Rates in Bladder Cancer Subset
- A Fellow Cancer Survivor Gives Me a Useful Message
- AACR 2025: Tailored Treatment Guided by Combined Tissue and Liquid Biopsies May Improve Outcomes in Advanced Solid Tumors